Clinical trials: Patients with Advanced Solid Tumors
Advanced Solid Tumors, Neoplasms
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer
- Trial name
- NCT00879684
- Testing
- CVX-060
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Solid Tumors
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a…
- Trial name
- NCT00635284
- Testing
- ABI-009
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celgene
Cancer, Oncology
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
- Conditions
- Cancer, Oncology, Tumors, Advanced Malignancy
- Trial name
- NCT00813384
- Testing
- AMG 208
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Amgen
Metastatic Non-Small Cell Lung Cancer, NSCLC
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
- Trial name
- PRESERVE 4 (NCT04863248)
- Testing
- Trilaciclib, Docetaxel
- Where
- 12 sites in United States
- Volunteers
- 10 people
- Sponsor
- G1 Therapeutics, Inc.
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no…
- Trial name
- NCT06948955
- Testing
- Bezuclastinib, Sunitinib
- Where
- 26 sites in United States
- Sponsor
- Cogent Biosciences, Inc.
Advanced Solid Malignancies, Malignant Lymphoma
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid…
- Trial name
- NCT01588548
- Testing
- AZD1208
- Where
- 3 sites in Japan, United Kingdom
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Advanced Cancer, Metastatic Cancer
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
- Trial name
- NCT05162443
- Testing
- adagrasib (MRTX849)
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V…
- Trial name
- NCT07826585
- Testing
- CRTKVA11-03 TCR-T Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Advanced Solid Tumors
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs.
- Trial name
- NCT04069026
- Testing
- BAY2416964
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 78 people
- Sponsor
- Bayer
Histologically-proven and Radiologically-confirmed Solid Tumors
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
This study is designed to obtain pharmacokinetic data following a single-dose 20-minute i.v. administration of ASA404 (900, 1200, or 1800 mg/m2) in adult cancer patients with varying degrees of hepatic impairment.
- Trial name
- NCT01278849
- Testing
- ASA404
- Where
- 4 sites in Italy, New Zealand
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
- Trial name
- NCT06474455
- Testing
- SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumours
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of…
- Trial name
- NCT04949425
- Testing
- Adavosertib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Advance Solid Tumors
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung…
- Trial name
- NCT07529535
- Testing
- ALK-N001 for Injection
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Anglikang Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors
- Trial name
- NCT03792958
- Testing
- CM082
- Where
- China
- Volunteers
- 19 people
- Sponsor
- AnewPharma
Advanced/Metastatic Solid Tumors
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy…
- Trial name
- NCT07102004
- Testing
- MHB088C for Injection
- Where
- China
- Volunteers
- 515 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumors, Non Small Cell Lung Carcinoma
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Phase 1A/B, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate the administration of EC1456 in advanced solid tumors.
- Trial name
- NCT01999738
- Testing
- EC1456 and EC20
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Endocyte
Advanced Solid Tumor
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
- Trial name
- NCT05170958
- Testing
- LBL-024 for Injection
- Where
- 49 sites in China
- Volunteers
- 396 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Lymphoma, Malignant, Advanced Solid Neoplasms
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.
- Trial name
- NCT03359733
- Testing
- TAK-659
- Where
- 3 sites in United States
- Sponsor
- Calithera Biosciences, Inc
Cancer
Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing…
- Trial name
- NCT00528047
- Testing
- PRLX 93936
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Prolexys Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.